Efficacy of peripheral deposition of inhaled rhDNase in CF patients during a respiratory tract exacerbation  by Bakker, E.M. et al.
S62 7. Pulmonology
239 Efﬁcacy of peripheral deposition of inhaled rhDNase in
CF patients during a respiratory tract exacerbation
E.M. Bakker1, S. Volpi2, E. Salonini2, B. Mu¨llinger3, P. Kroneberg3, W.C.J. Hop4,
B.M. Assael2, H.A.W.M. Tiddens1,5. 1Erasmus MC − Sophia Children’s Hospital,
Pediatric Pulmonology, Rotterdam, Netherlands; 2Azienda Ospedaliera di Verona,
Cystic Fibrosis Centre, Verona, Italy; 3Activaero GmbH, Gemu¨nden, Germany;
4Erasmus MC − Sophia Children’s Hospital, Epidemiology and Biostatistics,
Rotterdam, Netherlands; 5Erasmus MC, Radiology, Rotterdam, Netherlands
Introduction: Increased sputum production during a respiratory tract exacerbation
(RTE) can result in preferential deposition of nebulized rhDNase in central air-
ways. More efﬁcient deposition of rhDNase in peripheral airways might improve
mobilization of sputum from these airways.
Aim: To compare efﬁcacy of rhDNase nebulization targeted to the peripheral
airways with that of rhDNase targeted to central airways in CF patients with a
RTE.
Methods: Inclusion criteria: CF, admitted for RTE, FVC> 40%. Randomized
controlled, double blind, clinical trial in 2 CF centres. Primary endpoint FEF75.
Day 1−5 run-in: rhDNase inhalation with conventional nebulizer. Day 6 switch to
Akita® nebulizer and randomization to:
– peripheral setting: MMAD 3.0mm, slow inhalation, aerosol bolus at start of
breath; or
– central setting: MMAD 6.0mm, normal inhalation, aerosol bolus in middle of
breath. Minimal treatment duration with Akita®: 7 days. ANOVA analysis was
performed.
Results: 39 CF patients included, 17 male. Mean age 21 yrs. Spirometry at start of
study: FVC 74%; FEV1 58%; FEF75 21% pred. 37 patients completed the study.
Treatment effect for peripheral versus central was a factor 1.15, 95% CI 0.9−1.5,
p = 0.3 (poster ﬁgs. 1−3). For FEV1 similar results were found. Treatment effect
might be age dependent (poster ﬁg. 4).
Conclusions: In this pilot study there was no signiﬁcant difference in treatment
effect between peripheral and central deposition of inhaled rhDNase in CF patients
during a RTE. However, lung function and responses varied widely between patients.
It is well possible that this study was underpowered to observe a signiﬁcant
difference. A similar study is stable CF patients is ongoing.
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Bronchial obstruction is a possible complication of inhaled hypertonic saline (HS),
such that a premedication with bronchodilators is suggested. Adding hyaluronic
acid (HA) to HS (HAHS) has been recently shown to partially protect patients
from intolerance symptoms induced by HS [1]. However, the protective effect of
HAHS on bronchial hyper-reactivity is not documented yet.
The aim of the present study was to evaluate the presence of induced bronchocon-
striction after a single inhaled dose of HS and HAHS.
36 CF patients (12 M, 24 F) aged 11−45 yrs entered the study. On two separate
days patients inhaled HS (5.8% NaCl, 4ml) and HAHS (7% NaCl + 0.1% HA,
5ml) in random order. Lung function testing was performed at baseline, after the
inhalation of salbutamol 200mcg and after HS/HAHS. The change (D) in lung
function parameters before salbutamol and after HS/HAHS was considered. A
signiﬁcant bronchoconstriction was deﬁned as a drop in FEV1 of at least 12%
(or 200ml) after HS/HAHS when compared to baseline.
Overall, no difference was found between HS and HAHS for DFEV1/FVC
(1.6±4.0 vs 3.0±4.0 respectively), DFVC (−3.2±4.0 vs −3.6±6.5 %pr.) and DFEV1
(−0.4±4.0 vs 0.2±3.6 %pr.), whereas DMEF50 was signiﬁcantly increased after
HAHS (0.7±24.2 vs 5.5±10.2 %pr., p = 0.02). Five patients (14%) experienced
signiﬁcant bronchial obstruction after HS. In two of them (6%) airway narrowing
was induced by HAHS as well. No patient showed bronchial obstruction after HAHS
alone.
The present study shows that HS induced bronchial obstruction more frequently than
HAHS, suggesting a possible protective role of HA on bronchial hyper-reactivity.
Reference(s)
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Rationale: Use of nebulized tobramycin is a relevant treatment for controlling
chronic infection of Pseudomona aeruginosa in cystic ﬁbrosis patients. Many
commercial brands of tobramycin are available in the market. To characterize in vitro
properties of a generic tobramycin is necessary to evaluate not only the suspension
but also the ability to generate acceptable particles to deeply achieve the smaller
airways when the suspension is nebulized.
Objective: To compare the dispersion of size of particles obtained with a generic
tobramycin (Tobradosa ™) with the orginal (Tobi ™).
Methods: Particles size was determined through a lasser difractor analyzer (Malvern
Sizer) during the nebulization of Tobradosa or Tobi with a Pari Jet nebulizer and a
Devilbiss compressor. Three determinations were done for each medication.
Results: Average median diameter (± geometric standard deviation) was
4.83±2.2mm and 5.29±1.8mm (NS) for Tobradosa and Tobi respectively. Percent-
age of particles smaller than 4.8mm was 54.3% and 56.9% (NS), and smaller than
3.1mm was 34.8% and 38.4% (NS) for Tobradosa and Tobi respectively.
Conclusion: Particles size obtained during nebulization of a generic tobramycin
(Tobradosa ™) was similar to that of the original tobramycin (Tobi ™).
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Introduction: The subject of study was to examine the inﬂuence of Sidestream®
[Respironics, UK] nebulizer equipment and the value of compressed air pressure
from the NEBSTEER® pneumodosimeter [abcMED, PL] on the distribution of
aerosol particle size of rhDNase [Pulmozyme®, Roche CH]. Sidestream® nebulizer
with TV-connector or BCTS-head® is ventilated but with T-connector is non
ventilated nebulizer. NEBSTEER® is PC spirometer with dosimeter using to
administer aerosol by pneumatic or pneumodosimetric method. The device has the
possibility to programme the dose and the time of administration of aerosol basing
on the constant analysis of breathing.
Methods: Aerosol’s dose and particle size were measured by laser diffraction
method.
Results: The study demonstrated statistically signiﬁcant inﬂuence of air pressure
on aerosol particle size. For Sidestream® nebulizer with T-connector (non ven-
tilated), MMAD value was 0.54; 0.89 and 0.93 mm for air pressure 0.6, 0.8 and
1.0 bar respectively. For Sidestream® nebulizer with BCTS-head, MMAD value
was 0.41mm for air pressure 1.0 bar, whereas for Sidestream® nebulizer with TV-
connector (ventilated) the change of air pressure for 0.6, 0.8 and 1 bar causes the
change of MMAD value for 2.24, 3.69 and 4.27 mm respectively. This change differs
statistically signiﬁcant in comparison to the inﬂuence of the air pressure on aerosol
particle diameter for non-ventilated set and ventilated set with BCTS-head.
Conclusion: The individual adaptation of the aerosol particle diameter and air ﬂow
during inspiration enables optimization of inhalation treatment.
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